On January 14, the Experimental Drug Research and Development Center under the Agency for Science, Technology and Research (A*STAR) of Singapore recently developed a 3CL protease inhibitor, which will be used in the development of oral drugs for the new coronavirus in Singapore.
In 2019, A*STAR established the Singapore Experimental Drug Research and Development Centre (EDDC) to strengthen the biomedical field in Singapore. Recently, the Experimental Drug Research and Development Center has successfully developed a 3CL protease inhibitor.
The main protease in the new coronavirus is 3CL protease, and 3CL protease inhibitors prevent the virus from self-replication by inhibiting the expression of 3CL protease. This time, Singapore has developed a technology that can inhibit this protein, which is very effective against the new coronavirus and its variant strains. This is also the key technology used in Pfizer's new coronavirus oral medicine.
On the 14th, China Genting Xinyao and Singapore's Experimental Drug Research and Development Center announced that they had reached a global license agreement to jointly develop and produce oral drugs for the new coronavirus. It is reported that the clinical trial plan of this new coronavirus oral drug will start in the second half of this year.
